Today, we make history... again! The FDA has officially approved Gomekli (mirdametinib) - the second-ever…
Childrens Tumor FoundationFebruary 11, 2025
NF affects 1 in every 2,000 births
NF refers to genetic conditions that cause tumors to grow on nerves throughout the body. NF includes all forms of neurofibromatosis and schwannomatosis and affects about 4 million people worldwide. Anyone can be born with NF, and it affects everyone differently. There is no cure yet.
2
FDA-approved drugs for NF, and more are being researched
Koselugo (selumetinib) and Gomekli (mirdametinib) are the only FDA-approved drugs for NF1. CTF-funded research paved the way for these approvals.
3X
the number of NF clinical trials in the past 10 years
There are currently 67 active clinical trials for NF – three times the number of trials than just ten years ago!
47
years of funding NF research
The Children’s Tumor Foundation was founded nearly 50 years ago as the first grassroots organization to support patients with all types of NF.
11,000
have joined the NF Registry
The NF Registry is a secure website where people with NF can take an active role in the search for better treatments.
20,000
patients each year visit the NF Clinic Network
The NF Clinic Network (NFCN) is the first nationwide network focused on enhancing clinical care and best practices for NF treatment.
CTF Knowledge Base
What are you looking for?
Search our website for news and information about NF.
Latest News
Young Investigator: Q&A with Sarah Morrow about NF1 and MPNST
The Young Investigator Award (YIA) provides two-year salary support to early-career NF researchers to help…
Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of NF1
Healx has dosed the first patient in its Phase 2 trial for HLX-1502 - the…
Young Investigator: Q&A with Sarah Morrow about NF1 and MPNST
The Young Investigator Award (YIA) provides two-year salary support to early-career NF researchers to help…
Children’s Tumor Foundation Chair Pens Message Urging Restoration of NF Research Funding
In an op-ed published in RealClearHealth, Gabriel Groisman, Chair of the Children's Tumor Foundation, calls…
Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of NF1
Healx has dosed the first patient in its Phase 2 trial for HLX-1502 - the…
Sign Up for our Newsletter
Join our mailing list for news, exclusive resources, events and opportunities.
"*" indicates required fields
